Further analysis is needed to distinguish genetic changes that occur in the primary viral population from apparent changes to clarify whether such escape mutants are enough to spread and persist in human beings and how SARS-CoV-2 displays compartmentalized replication. experienced received 1 injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine (BNT162b2; Pfizer/BioNTech, https://www.pfizer.com) 20 days earlier, we Lotilaner confirmed a analysis of COVID-19 by using a semiquantitative SARS-CoV-2 reverse transcription PCR (RT-PCR) viral weight assay. This assay showed a cycle threshold (Ct) value of 27 for any nasopharyngeal swab specimen. His most recent monoclonal antibody (mAb) chemotherapy treatment (venetoclax and rituximab) had been carried out 17 days earlier. Because of his immunocompromised status, treatment with bamlanivimab (LY-CoV555), a neutralizing IgG1 mAb, was initiated at day time 0, 4 days after onset of symptoms (Table). The patient received an infusion of 700 mg in one dose and was discharged. Table Clinical and biological characteristics of immunocompromised patient given bamlanivimab for COVID-19, France* thead th valign=”bottom” align=”remaining” scope=”col” rowspan=”1″ colspan=”1″ Disease program, day time? /th th valign=”bottom” align=”center” scope=”col” rowspan=”1″ colspan=”1″ Clinical manifestations /th th valign=”bottom” align=”center” scope=”col” rowspan=”1″ colspan=”1″ Treatment/action /th th valign=”bottom” align=”center” scope=”col” rowspan=”1″ colspan=”1″ Clinical samples? /th th valign=”bottom” align=”center” scope=”col” rowspan=”1″ colspan=”1″ RT-PCR results (mean Ct value) /th th valign=”bottom” align=”center” scope=”col” rowspan=”1″ colspan=”1″ VirSNIP Kit results /th th valign=”bottom” align=”center” scope=”col” rowspan=”1″ colspan=”1″ NGS clade /th /thead ?20 hr / hr / First dose mRNA vaccine hr / hr / hr / hr / hr / ?17 hr / hr / Venetoclax, rituximab hr / hr / hr / hr / hr / ?4 hr / Cough, fever, diarrhea, asthenia hr / NA hr / hr / hr / hr / hr / ?3 hr / hr / hr / NP hr / Positive (27)? hr / NA hr / NA hr / 0 hr / hr / Bamlanivimab (700 mg) hr / hr / hr / hr / hr / 3 hr / hr / hr / NP hr / Positive (20) hr / E484, N501Y hr / 20I/501Y.V1 hr / hr / hr / hr / Blood hr / Positive (37) hr / NA hr / NA hr / hr / hr / hr / Serum (30.7) hr / hr / hr / hr / 6 hr / hr / Hospitalized at infectious diseases division hr / NP hr / Positive (21) hr / E484Q, N501Y hr / 20I/501Y.V1 + E484Q hr / hr / hr / hr / Blood hr / Negative hr / NA hr / NA hr / 7 hr / hr / hr / Serum (23.2) hr / hr / hr / hr / 10 hr / hr / Convalescent-phase plasma hr / NP hr / Positive (17) hr / E484Q, N501Y hr / 20I/501Y.V1 + E484Q hr / 11 hr / hr / hr / NP hr / Positive (19) hr / E484Q, N501Y hr / 20I/501Y.V1 + E484Q hr / hr / hr / hr / Blood hr / Positive (30) hr / E484, N501Y hr / 20I/501Y.V1 493R hr / hr / hr / High-flow nose oxygen hr / Serum (26.5) hr / hr / hr / hr / 13 hr / hr / Transferred to ICU hr / hr / hr / hr / hr / 15 hr / hr / hr / NP hr / Positive (21) hr / E484Q, N501Y hr / 20I/501Y.V1+E484Q hr / 17 hr / hr / hr / Blood hr / Positive (31) hr / E484, N501Y hr / 20I/501Y.V1 493R 484K 484Q hr / hr / hr / hr / Serum (22.9) hr / hr / hr / hr / 21 hr / hr / High-dose corticotherapy protocol hr / hr / hr / hr / hr / 26 hr / hr / High-dose corticotherapy protocol hr / hr / hr / hr / hr / 33 hr / hr / Transferred to infectious disease department hr / NP hr / Positive (17) hr / E484Q, N501Y hr / 20I/501Y.V1 + E484Q hr / hr / Improvement in respiratory condition hr / NA hr / Blood hr / Positive (37) hr / NA hr / NA hr / hr / hr / hr / Serum (30.8) hr / hr / hr / hr / 39 hr / hr / hr / NP hr / Positive (17) Lotilaner hr / E484Q, N501Y hr / 20I/501Y.V1 + E484Q hr / hr / hr / hr / Blood hr / Negative hr / hr / hr / hr / hr / hr / Serum (18.6) hr / hr / hr / hr / 45 hr / hr / hr / NP hr / Positive (20) hr / E484Q, N501Y hr / Lotilaner 20I/501Y.V1 + E484Q hr / 47 hr / hr / Treatment with remdesivir (10 d) hr / hr / hr / hr / hr / 52 hr / hr / hr / NP hr / Positive (31) hr / E484Q, N501Y hr / 20I/501Y.V1 + E484Q hr / 54 hr / hr / hr / NP hr / Positive (30) hr / E484Q, N501Y hr / 20I/501Y.V1 + E484Q hr / 56 hr / hr / Hospitalization for follow-up care hr / hr / hr / hr / hr / 61 hr / hr / hr / NP hr / Negative hr / NA hr / NA hr / 80NPNegativeNANA Open in a separate window *Blank cells indicate Lotilaner that clinical status was stable on that day time, and no treatment was given. COVID-19, coronavirus disease; Ct, cycle threshold; D, day time; ICU, intensive care unit; NA, not available; NP, nasopharyngeal swab specimen; NGS, next-generation sequencing; RT-PCR, Rabbit Polyclonal to MRPL16 reverse transcription PCR. ?Day time 0 indicates 1st day time of follow-up care at hospital. ?Serologic results given by using the Wantai antibody test (index of positivity = 1). Vaccine BNT162b2 (Pfizer/BioNTech, https://www.pfizer.com). ?Test was performed in an external laboratory (no sample was available for further analysis). Analysis of samples showed a high viral load inside a nasopharyngeal swab specimen (Ct 20) and a blood sample (Ct 37) (Table). Three days after the mAb infusion,.
Categories